LX
LXEO.US Lexeo Therapeutics, Inc. Common Stock
- Market cap
- USD 265M
- P/E
- -
- P/B
- 1.00x
- ROE
- -39.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is LXEO.US undervalued?
Graham numberThe Graham number of Lexeo Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Lexeo Therapeutics, Inc. Common Stock fundamental analysis
No fundamental analysis for Lexeo Therapeutics, Inc. Common Stock yet.
Lexeo Therapeutics, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Lexeo Therapeutics, Inc. Common Stock
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP…
Full company profileLexeo Therapeutics, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Lexeo Therapeutics, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 518K | 1.66M | 654K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 518K | 1.66M | 654K | -1.84M | -2.00M | -2.08M | - |
| Operating Income | -4.59M | -50.6M | -60.5M | -68.5M | -106M | -109M | -101M |
| EBITDA | -4.59M | -50.6M | -58.0M | -64.3M | -96.2M | -97.7M | -89.9M |
| Net Income | -5.15M | -50.6M | -59.3M | -66.4M | -98.3M | -100.0M | -92.1M |
| EPS | -0.20 | -2.01 | -2.36 | -2.49 | -3.09 | -1.86 | -1.08 |
| Balance Sheet | |||||||
| Total Assets | 29.4M | 137M | 97.1M | 140M | 147M | 269M | 255M |
| Total Liabilities | 34.9M | 192M | 210M | 26.3M | 30.1M | 22.0M | 19.8M |
| Shareholders' Equity | -5.54M | -55.6M | -113M | 114M | 117M | 247M | 235M |
| Cash & Short-term Investments | 29.4M | 136M | 77.3M | 121M | 122M | 182M | 212M |
| Total Debt | 3.01M | - | 13.5M | 11.6M | 9.92M | 7.89M | 6.81M |
| Cash Flow | |||||||
| Operating Cash Flow | -3.13M | -44.2M | -54.6M | -59.5M | -81.2M | -98.6M | -77.5M |
| Capital Expenditure | 0.00 | 188K | 901K | 165K | 481K | 397K | 84.0K |
| Free Cash Flow | -3.13M | -44.4M | -55.5M | -59.7M | -81.6M | -99.0M | -77.6M |
| Ratios | |||||||
| ROE | - | - | - | -58.5% | -84.2% | -40.5% | -39.2% |
| ROA | -17.5% | -37.0% | -61.1% | -47.5% | -66.9% | -37.2% | -36.1% |
| Net Profit Margin | -993.8% | -3,055.0% | -9,063.8% | - | - | - | - |
| Debt to Equity | - | - | - | 0.10x | 0.08x | 0.03x | 0.03x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Lexeo Therapeutics, Inc. Common Stock dividends
Lexeo Therapeutics, Inc. Common Stock has not paid dividends in the last 6 fiscal years.
Who owns Lexeo Therapeutics, Inc. Common Stock
- Insiders 1.05%
- Institutions 98.95%
- Public & others 0.00%
- Shares outstanding 82.1M
- Free float 49.8M
Top funds holding LXEO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 2.34M | 2.84% | 0.00% | Sep 2026 |
| JPMorgan Small Cap Growth A | 2.10M | 2.55% | -0.61% | Sep 2026 |
| iShares Russell 2000 ETF | 1.81M | 2.20% | 0.00% | Oct 2026 |
| State Street® SPDR® S&P® Biotech ETF | 1.70M | 2.07% | +2.69% | Oct 2026 |
| abrdn Life Sciences Investors | 1.69M | 2.06% | +31.54% | Oct 2026 |
| Fidelity Small Cap Index | 777K | 0.95% | 0.00% | Aug 2026 |
| Biotech Growth Ord | 745K | 0.91% | 0.00% | Jul 2026 |
| JPMorgan Small Cap Blend A | 665K | 0.81% | -1.63% | Sep 2026 |
| iShares Russell 2000 Value ETF | 665K | 0.81% | 0.00% | Oct 2026 |
| Janus Henderson Glb Life Scn I2 USD | 576K | 0.70% | +0.31% | Aug 2026 |
| Stt Strt®SPDR®S&PKenshoNwEcosComposETF | 566K | 0.69% | +0.08% | Oct 2026 |
| iShares Biotechnology ETF | 539K | 0.66% | -0.19% | Oct 2026 |
| Vanguard Russell 2000 ETF | 413K | 0.50% | +1.08% | Sep 2026 |
| Fidelity Extended Market Index | 342K | 0.42% | +5.38% | Sep 2026 |
| Fidelity Enhanced Small Cap Core ETF | 305K | 0.37% | +0.27% | Oct 2026 |
| Northern Small Cap Value | 261K | 0.32% | 0.00% | Sep 2026 |
| Multi-Manager Small Cap Eq Strat Inst | 261K | 0.32% | -8.16% | Sep 2026 |
| Dimensional US Small Cap ETF | 254K | 0.31% | 0.00% | Oct 2026 |
| Janus Henderson Global Life Sciences D | 246K | 0.30% | -56.19% | Sep 2026 |
| DFA U.S. Small Cap I | 242K | 0.30% | +4.39% | Sep 2026 |
Top institutions holding LXEO.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 6.38M | 7.78% | +410.74% | Jun 2026 |
| Affinity Asset Advisors, LLC | 5.81M | 7.07% | +15.00% | Jun 2026 |
| BlackRock Inc | 5.74M | 6.99% | +12.30% | Jun 2026 |
| RA Capital Management, LLC | 5.00M | 6.09% | 0.00% | Jun 2026 |
| Frazier Life Sciences Management, L.P. | 4.82M | 5.88% | +9.04% | Jun 2026 |
| State Street Corp | 4.35M | 5.31% | +22.04% | Jun 2026 |
| Vestal Point Capital LP | 4.32M | 5.26% | -3.46% | Jun 2026 |
| Paradigm Biocapital Advisors LP | 4.18M | 5.09% | -32.48% | Jun 2026 |
| Jupiter Topco LLC | 3.95M | 4.82% | 0.00% | Jun 2026 |
| Orbimed Advisors LLC | 3.95M | 4.81% | +9.59% | Jun 2026 |
| Citadel Advisors Llc | 3.90M | 4.75% | +1.66% | Jun 2026 |
| Vanguard Capital Management, LLC | 3.13M | 3.81% | +3.95% | Jun 2026 |
| Millennium Management LLC | 2.83M | 3.45% | +75.70% | Jun 2026 |
| Nantahala Capital Management, LLC | 2.60M | 3.17% | +116.67% | Jun 2026 |
| Woodline Partners LP | 2.50M | 3.05% | -9.09% | Jun 2026 |
| Balyasny Asset Management LLC | 2.41M | 2.94% | +51.78% | Jun 2026 |
| The Goldman Sachs Group Inc | 2.15M | 2.62% | +10.24% | Jun 2026 |
| Geode Capital Management, LLC | 1.75M | 2.13% | +15.47% | Jun 2026 |
| ADAR1 Capital Management LLC | 1.57M | 1.91% | +6.72% | Jun 2026 |
| venBio Select Advisor LLC | 1.49M | 1.81% | -20.58% | Jun 2026 |
Lexeo Therapeutics, Inc. Common Stock company profile
- Company name
- Lexeo Therapeutics, Inc. Common Stock
- Ticker
- LXEO.US
- Exchange
- USA Stocks
- Listed since
- Nov 3, 2023
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 63
- Fiscal year end
- December
- Address
- 345 Park Avenue South, New York, NY, United States, 10010
- Phone
- 212 547 9879
- Website
- lexeotx.com
About Lexeo Therapeutics, Inc. Common Stock
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company is also developing LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, LX1020, and LX1021, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has a license agreement with Cornell University to conduct the Phase 1/2 clinical trial of LX1001, as well as support the development of the LX1004 program; a research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.
Lexeo Therapeutics, Inc. Common Stock management
8- Mr. R. Nolan Townsend M.B.A.CEO & Director · born 1981
- Mr. Louis TamayoCFO & Principal Accounting Officer · born 1977
- Dr. Ronald G. Crystal M.D.Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory Board
- Dr. Jose Manuel Otero Ph.D.Chief Operating Officer · born 1979
- Dr. Narinder P. Bhalla FACC, FSCAI, M.D.Chief Medical Officer · born 1964
- Mr. Keith WonnacottSenior Vice President of Regulatory Affairs
- Ms. Ashley KaplowitzHead of Capital Markets
- Mr. Ryan McHenryVP & Corporate Controller